Global Mavacamten Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Mavacamten market size was valued at US$ 986 million in 2025 and is forecast to a readjusted size of US$ 7355 million by 2032 with a CAGR of 18.4% during review period.
Mavacamten is an oral, selective, allosteric inhibitor of cardiac myosin, designed to treat obstructive hypertrophic cardiomyopathy (HCM) by reducing excessive myocardial contractility and improving left ventricular outflow tract obstruction. It modulates actin-myosin cross-bridge formation in a reversible manner, thereby alleviating symptoms such as dyspnea, fatigue, and chest pain while enhancing exercise capacity in patients with symptomatic HCM. As a first-in-class targeted therapy, mavacamten offers a novel pharmacological approach beyond conventional beta-blockers and calcium channel blockers, demonstrating favorable efficacy and safety profiles in clinical trials and becoming an important treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy.In 2025, global Mavacamten production reached approximately 12 million units.
As the first-in-class cardiac myosin inhibitor approved globally, mavacamten has established a core position in the treatment of obstructive hypertrophic cardiomyopathy (oHCM), a rare disease with a long-standing high unmet medical need, owing to its pioneering nature and well‑defined clinical efficacy. Its launch has completely transformed the traditional treatment paradigm, which relied on beta‑blockers, calcium channel blockers, and surgical interventions. By precisely targeting the underlying pathogenesis of the disease, mavacamten significantly improves cardiac function and quality of life in patients. On the global market, the drug has rapidly built brand barriers and established market dominance through its first‑mover advantage and robust physician education programs. In the Chinese market, its successful inclusion in medical insurance has greatly improved accessibility, making it a key driver of the drug’s global growth. Competition in the market is becoming increasingly fierce, with new drugs of the same mechanism entering the market one after another and exerting diversion pressure through differentiated advantages such as convenient administration. This has prompted mavacamten to consolidate its leading position by continuously expanding its indications, accumulating long‑term real‑world data, and optimizing treatment regimens. Overall, the targeted therapy market for hypertrophic cardiomyopathy, in which mavacamten operates, is undergoing rapid expansion. The industry focus is shifting from conventional symptom management to precise etiological treatment, and the market will continue to evolve driven by multiple factors including indication expansion, increased market penetration, and optimization of the competitive landscape.
This report is a detailed and comprehensive analysis for global Mavacamten market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Mavacamten market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mavacamten market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mavacamten market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mavacamten market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mavacamten
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mavacamten market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include MyoKardia, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Mavacamten market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
2.5 mg
5 mg
Market segment by Combination Therapy
Combination with Beta-Blockers
Combination with Calcium Channel Blockers
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Treatment Of Obstructive Hypertrophic Cardiomyopathy
Improvement Of Cardiac Function
Relief Of Symptoms Such As Dyspnea And Fatigue
Others
Major players covered
MyoKardia
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Mavacamten product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Mavacamten, with price, sales quantity, revenue, and global market share of Mavacamten from 2021 to 2026.
Chapter 3, the Mavacamten competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Mavacamten breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Mavacamten market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Mavacamten.
Chapter 14 and 15, to describe Mavacamten sales channel, distributors, customers, research findings and conclusion.